Hysingla Er Tablet, Extended Release
Product Images NDC 59011-271

11 FDA label images from Knoa Pharma Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Hysingla Er (NDC 59011-271). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Knoa Pharma Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Hysingla 01)

Figure 1 (Hysingla 01)
A line graph depicting the percentage of subjects against the percent reduction in Emax of drug liking for manipulated Hysingla ER compared to powdered hydrocodone following intranasal administration. The x-axis represents incremental percent reductions from >0 to ≥100, while the y-axis shows the corresponding percentage of subjects from 0 to 100%. The line shows a downward trend in the percentage of subjects as percent reduction increases.*
FDA Label Image

Figure 2 (Hysingla 02)

Figure 2 (Hysingla 02)
A line graph depicting the percentage of subjects versus percent reduction in Emax of drug liking for chewed Hysingla ER compared to hydrocodone solution after oral administration. The x-axis represents the percent reduction categories from >0 to >=100, and the y-axis shows the percentage of subjects from 0 to 100%. The graph line shows a descending trend as percent reduction increases.*
FDA Label Image

Chemical Structure (Hysingla 03)

Chemical Structure (Hysingla 03)
Chemical structure of the active ingredients in Hysingla ER, showing the molecular formula of the extended-release opioid hydrocodone bitartrate dihydrate with detailed arrangement of atoms and bonds.*
FDA Label Image

Chemical Structure (Hysingla 04)

Chemical Structure (Hysingla 04)
A line graph comparing hydrocodone plasma concentration (ng/mL) over 24 hours between Hysingla ER 30 mg (one tablet every 24 hours for 3 days) and IR Hydrocodone Bitartrate 7.5 mg (one tablet every 6 hours for 3 days). The x-axis represents time in hours, and the y-axis shows hydrocodone plasma concentration. The graph illustrates the sustained release profile of Hysingla ER compared to the fluctuating levels of the immediate-release form.*
FDA Label Image

Chemical Structure (Hysingla 05)

Chemical Structure (Hysingla 05)
A cumulative proportion graph showing the percent improvement from screening on the x-axis versus the proportion of subjects responding on the y-axis. The chart compares treatment groups for Hysingla ER and placebo, with Hysingla ER showing a higher proportion of subjects responding across most improvement percentages.*
FDA Label Image

Principal Display Panel (30 mg Tablet Bottle Label)

Principal Display Panel (30 mg Tablet Bottle Label)
Hysingla ER 30 mg extended-release tablets label showing hydrocodone bitartrate as the active ingredient. The label indicates 60 tablets per container and is labeled for Rx only. Instructions emphasize swallowing tablets whole without cutting, breaking, chewing, crushing, or dissolving. The product is labeled by Knoa Pharma LLC.*
FDA Label Image

Principal Display Panel (20 mg Tablet Bottle Label)

Principal Display Panel (20 mg Tablet Bottle Label)
Hysingla ER 20 mg extended-release tablets label showing strength, active ingredient hydrocodone bitartrate, package count of 60 tablets, and directions to swallow tablets whole without cutting or crushing. Labeler is Knoa Pharma LLC. Includes a dispenser warning to provide medication guide upon dispensing.*
FDA Label Image

Principal Display Panel (40 mg Tablet Bottle Label)

Principal Display Panel (40 mg Tablet Bottle Label)
Label for Hysingla ER 40 mg extended-release tablets containing hydrocodone bitartrate. The label indicates a package of 60 tablets, for prescription use only, with instructions to swallow tablets whole without cutting, breaking, chewing, crushing, or dissolving. The labeler is Knoa Pharma LLC.*
FDA Label Image

Principal Display Panel (60 mg Tablet Bottle Label)

Principal Display Panel (60 mg Tablet Bottle Label)
Label for Hysingla ER 60 mg extended-release tablets containing hydrocodone bitartrate. The label indicates a count of 60 tablets, with directions to swallow tablets whole and warnings against cutting, breaking, chewing, crushing, or dissolving. Dispensed by Knoa Pharma LLC. The label includes usage and storage information, a barcode, and an Rx only designation.*
FDA Label Image

Principal Display Panel (80 mg Tablet Bottle Label)

Principal Display Panel (80 mg Tablet Bottle Label)
Label for Hysingla ER 80 mg extended-release tablets containing hydrocodone bitartrate, manufactured by Knoa Pharma LLC. The bottle contains 60 tablets, with instructions to swallow tablets whole and not to cut, break, chew, crush, or dissolve. Includes a caution that an accompanying Medication Guide must be provided upon dispensing. Storage directions and labeler address are also visible.*
FDA Label Image

Principal Display Panel (100 mg Tablet Bottle Label)

Principal Display Panel (100 mg Tablet Bottle Label)
Label for Hysingla ER 100 mg extended-release tablets containing hydrocodone bitartrate. The label indicates a quantity of 60 tablets and includes dispensing instructions emphasizing swallowing tablets whole without cutting or crushing. The product is labeled for prescription use by Knoa Pharma LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.